BMS is awaiting Phase III readouts from potential Eliquis successor, milvexian and schizophrenia med, Cobenfy, expected later this year.

Estimates suggest fragmented technology can raise clinical trial costs by 45%, but a unified approach to clinical data management can enable efficiency.

Sales for Lilly blew past expectations in the quarter as demand for weight loss treatments showed no signs of abating.

LEO Pharma has signed a definitive agreement for the acquisition of Replay, which focuses on treating rare genetic dermatological conditions.

Axsome Therapeutics has received FDA approval for Auvelity to treat agitation associated with dementia due to Alzheimer’s.

Teva’s Emalex buyout falls under the company's wider strategy of prioritising deals around de-risked, differentiated, late-stage assets.